Is dihexa or semax better?

Semax, clearly. It scores 7.1 against dihexa's 4.4 and wins every scored cognitive use case: cognition focus 6.5 to 5.0, memory 6.0 to 5.5, neuroplasticity 6.0 to 5.0, neuroprotection 6.5 to 4.5. Semax also has human data behind it. Dihexa has none. The single exception is a documented research experiment around a neurodegenerative hypothesis.

Why is dihexa scored so low if it's more potent than BDNF?

Because potency measured in rats is not a benefit in a person. Dihexa's rodent synaptogenesis is real and unusually strong, but there are zero human RCTs, zero Phase 1 safety studies and no validated human route or dose. Wells 2024 also found no protection against motor, weight or cognitive deficits in 40 rats, so even the animal record is mixed.

What is the actual cancer concern with dihexa?

Dihexa works by potentiating HGF signaling at c-Met. Comoglio 2008 describes MET as a validated cancer invasion and metastasis target, and capmatinib and tepotinib were approved to block that receptor in MET-altered lung cancer. Dihexa has no carcinogenicity study and no long-term human exposure record. The concern stays theoretical for any individual, but it is pathway biology rather than a vague class worry, which is why cancer history is a hard contraindication.

How fast do they work?

Semax is fast. First noticeable effect in about an hour, assessment window of 2 weeks, full effect at 2 weeks. Dihexa's figures are estimated rather than measured: roughly 2 days to a first change, a 4-week assessment window and full effect at 4 weeks. Semax fails fast, which is a real advantage when neither compound is proven.

Can I stack dihexa and semax?

Don't. The two are mechanistically redundant: both are aiming at neurotrophic plasticity, dihexa through HGF and c-Met, semax through BDNF, TrkB and NGF. Running them together adds cost, sourcing risk and a c-Met exposure you cannot justify, and if you get a benefit or a bad reaction you will not know which compound produced it.

Who should avoid both?

Anyone pregnant or breastfeeding, and anyone competing in drug-tested sport. Dihexa additionally rules out active malignancy, personal or family cancer history, MET-driven tumors and anyone under 18. Semax additionally rules out seizure history, high baseline anxiety, unstable psychiatric symptoms, MAOI therapy and psychiatric medication without clinician clearance. Neither should be used indefinitely with no defined endpoint.

It's approved in Russia and sits on its Essential Drugs List, but it is unapproved in the US and sold as a research nasal spray with no product standard. Purity, concentration and storage are vendor-dependent, so purity verification matters. Dihexa has no approved product anywhere and is sold only as a gray-market research chemical.

Has Nick used either of these?

Semax yes, dihexa no. Semax was the first nootropic peptide I tried, and I still use it several times a month, primarily as a nasal spray. The effect feels subtle and situational for me. I have never run a dihexa cycle, and the missing human safety data is exactly why.

Head-to-Head Comparison

Dihexa vs Semax: Which Is Better for Memory and Focus?

Should I take dihexa or semax?

Reviewed 09/07/2026

Semax scores 7.1 against dihexa's 4.4, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human trials and stimulates c-Met, a pathway oncology drugs try to shut down. For most people, take neither, or take semax.

Semax 7.1 in the strong recommend tier, dihexa 4.4 in the caution tier. This is not a close call, and the matrix rows say the same thing the totals do.
Dihexa has zero human RCTs, zero Phase 1 safety studies and no validated human dose. Every efficacy claim behind it comes from rodents and cells.
Dihexa agonizes c-Met, the receptor capmatinib and tepotinib were approved to block in MET-altered lung cancer. Any personal or family cancer history rules it out.
Semax sits on Russia's Essential Drugs List with decades of supervised use, but its human record is post-stroke recovery, not healthy-adult cognition.
Costs are close: dihexa $30 to $60 a month before the per-lot purity testing it needs, semax $12 to $60. Price is not the deciding factor here.
Both are unapproved in the US and both carry anti-doping risk. Neither is a supplement decision, and confidence on this pair is low.

At a Glance

Option A

Dihexa

4.4 / 10 Caution

Upside

Efficacy 3.0
Breadth 2.0
Evidence 2.3
Speed 3.5
Durability 2.5
Bioindividuality 2.5

Downside

Safety Risk 3.3
Side Effects 2.2
Cost 2.9
Effort 2.1
Opportunity Cost 2.5
Dependency 1.8
Reversibility 2.9

Best at:

Memory 5.5
Cognition Focus 5.0
Neuroplasticity 5.0
Neuroprotection 4.5

Angiotensin IV analog acting through HGF and c-Met. BioHarmony 4.4, caution tier, confidence low.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
Cognition Focus	Semax	Semax 6.5 against dihexa 5.0, and the reason is the type of evidence, not the size of the gap. Semax has Russian human attention and operative-memory work (Asmarin 1997, Kaplan 1996) plus rat learning data from Dolotov 2006. Dihexa's cognition case is a research-chemical hypothesis with no human dose-response and no human outcome data at all.
Memory	Semax	Semax 6.0 against dihexa 5.5, the tightest row in the matrix, and semax still takes it. Both sides rest mostly on animals: Dolotov 2006 and Ellis 2020 for semax, McCoy 2013 and Sun 2021 for dihexa. Semax breaks the tie because some of its memory signal is human, and because dihexa's route and dose in people have never been established.
Neuroplasticity	Semax	Semax 6.0 against dihexa 5.0. Dihexa's plasticity claim is the more dramatic one: sub-nanomolar synaptogenesis in rats. Semax's is the better documented one: BDNF and TrkB upregulation in rat hippocampus after intranasal dosing. Potency that has never been measured in a person loses to a mechanism with a longer supervised human track record.
Neuroprotection	Semax	Semax 6.5 against dihexa 4.5, the widest cognitive gap here. Gusev 2018 reported BDNF and rehabilitation outcomes in 110 post-ischemic-stroke patients, backed by ischemia transcriptomics in Filippenkov 2020. Dihexa's neuroprotection case is Sun 2021 in APP/PS1 mice, and the c-Met concern caps how far that can be pushed.
Nerve Regeneration	Tie	Semax 4.5 against dihexa 3.5, and the subratings overstate the difference. Both sides are animal-only here. Weiss 2021 studied dihexa alongside stem cells and G-CSF in a rat sciatic nerve repair model, so dihexa's contribution is not isolated. Semax has Russian optic-nerve use with no accessible Western trial. Neither is validated in a person.
TBI	Semax	Semax 4.5 against dihexa 3.0, though neither has a dedicated traumatic-brain-injury trial. Semax borrows credibility from its neuroprotection and ischemia work in humans. Dihexa borrows it from rodent memory models. When both cases are indirect, take the one whose parent evidence involved people.
Geriatric	Semax	Semax 5.0 against dihexa 1.0, the largest gap in the matrix. Older adults are where semax's evidence actually lives, because stroke and neurorecovery are what Gusev 2018 studied. Dihexa's Alzheimer's rationale targets the same population but stops at Sun 2021 in mice, with no human geriatric trial and no safety data in a group already carrying cancer risk.
Longevity	Semax	Semax 3.5 against dihexa 1.0, and this row is decided by safety rather than benefit. Neither has a lifespan or dementia-prevention trial. Dihexa scores the floor because chronic c-Met agonism runs against longevity: Comoglio 2008 frames MET as a cancer invasion and metastasis pathway, and no carcinogenicity study exists.
Stress Resilience	Semax	Semax 4.0 against dihexa 1.0. Ellis 2020 supports hypoxia-stress memory protection in rats, which is a real if narrow resilience signal, and human cortisol and HRV endpoints are still missing. Dihexa has no stress, cortisol, autonomic or burnout endpoint of any kind, so the floor score reflects absence rather than a weak result.

Cost Comparison

Intervention	Monthly Cost	Notes
Dihexa	$30 to $60	Priced 2026-09-07, research-chemical channel, at 8 to 12 mg a day sublingual. The report prices community doses at $30 to $60 a month from gray-market vendors.That figure is before the per-lot HPLC and mass-spec identity testing the report says is mandatory, which can cost more than the peptide itself. Read the sticker price as a floor, not a budget.
Semax	$12 to $60	ESTIMATE, priced 2026-09-07, research-chemical channel, at 300 to 600 mcg a day of 0.1% spray. A pre-mixed 30 mg 0.1% nasal spray runs $40 to $100.At 300 mcg a day (9 mg a month) that works out to $12 to $30. At 600 mcg a day (18 mg a month) it is $24 to $60. These are estimated figures from typical vendor pricing, not a measured receipt.
The difference	Semax is cheaper at the low end, level at the top	At the bottom of each range semax costs $12 against dihexa's $30. At the top both land at $60 a month, so headline price barely separates them.Testing is what breaks the tie. Dihexa's $30 to $60 assumes no verification, and the report treats per-lot identity and purity testing as mandatory rather than optional. Cost should not be why you pick either one.

When to Switch

These two run on completely different clocks, which changes how you judge them. Semax gives a first noticeable effect in about an hour, and its assessment window and full effect both land at 2 weeks, so you know quickly whether it does anything for you. Dihexa's onset figures are estimated rather than measured: a first change around day 2, a 4-week assessment window, full effect at 4 weeks.

Start with semax and judge it at 2 weeks against a target you named in advance, such as a specific attention, memory or recovery problem. If it does nothing across a full window at 300 to 600 mcg a day, stop and work on sleep, training and baseline cognitive health rather than escalate to a compound with no human safety record. Moving to dihexa is only defensible for a documented experiment around a specific neurodegenerative hypothesis, with medical oversight, third-party purity testing, no cancer risk factors and a defined endpoint.

Do not overlap them: both aim at the same outcome through different receptors, so stacking adds cost and c-Met exposure without a mechanism story, and a benefit or a bad reaction could not be attributed to either one.

Who Should Pick What?

Experienced nootropic user who wants a peptide with some human record

Semax

Cognition focus 6.5 against 5.0, plus Russian human attention and operative-memory work behind it. Semax also fails fast: you get a first effect in about an hour and a verdict in 2 weeks, so a wasted experiment costs you two weeks and roughly $12 to $30.

Older adult working on neuroprotection or post-stroke recovery

Semax

Geriatric 5.0 against 1.0 and neuroprotection 6.5 against 4.5. Gusev 2018 studied exactly this population, 110 post-ischemic-stroke patients on semax plus rehabilitation. Do it with a clinician, and treat semax as an addition to real neurological care rather than a replacement for it.

Anyone with a personal or family history of cancer

Semax

Dihexa is out, not merely cautioned. Active malignancy, personal or family cancer history and MET-altered tumors are all listed contraindications, and c-Met agonism is the intrinsic mechanism rather than a side effect. Semax carries no equivalent oncology-pathway concern.

Athlete competing under anti-doping rules

Tie

Neither. Dihexa falls under WADA growth-factor and growth-factor-modulator language, and semax sits in S0 catch-all territory as a non-approved substance. Drug-tested sport eligibility is a listed contraindication on the semax side. Get formal sport-specific clearance before either, which in practice means not using them.

Pregnant, breastfeeding, or under 18

Tie

Neither, with no ambiguity. Pregnancy and breastfeeding are listed contraindications on both sides, and dihexa adds under 18 years old to that list. There is no prenatal or pediatric safety data for either compound, so there is nothing to weigh against.

Seizure history, high anxiety, or on psychiatric medication

Tie

Neither, and this is the row where the higher-scoring option is the one with the named warning. Seizure history, high baseline anxiety, unstable psychiatric symptoms, MAOI therapy and psychiatric medication without clinician clearance are all semax contraindications. Dihexa is not safer here, it is simply untested: its psychiatric safety file is empty rather than clean.

Researcher testing a specific neurodegenerative hypothesis

Dihexa

This is the one profile where dihexa is the answer, and it is narrow. McCoy 2013 and Sun 2021 give a mechanistic reason to look at synaptogenesis through HGF and c-Met. It requires medical oversight, per-lot identity and purity testing, no cancer risk factors and a defined endpoint. Wells 2024 is a reminder that the animal signal does not always replicate.

Research Highlights

Mechanism Difference
Dihexa and semax are mechanistically redundant. They attack the same target, neurotrophic plasticity, through different upstream receptors. Dihexa is an angiotensin IV analog that potentiates hepatocyte growth factor signaling at c-Met to drive dendritic spine formation.Semax works through BDNF and TrkB, NGF, cholinergic modulation, low-affinity melanocortin activity and enkephalin-degrading enzyme inhibition. Different receptors, one shared destination, which is why stacking them buys risk rather than coverage.
Safety Comparison
Safety is where this comparison stops being close. Dihexa scores 3.3 on safety risk against semax's 1.8, and the reason is specific: dihexa agonizes c-Met, the receptor capmatinib and tepotinib were approved to inhibit in MET-altered lung cancer.Both rule out pregnancy and breastfeeding. Dihexa adds active malignancy, cancer history, MET-driven tumors and anyone under 18. Semax adds seizure history, high baseline anxiety, unstable psychiatric symptoms and MAOI therapy. Semax's risks are manageable. Dihexa's are structural.
Cost Comparison
Dihexa runs $30 to $60 a month at 8 to 12 mg a day sublingual. Semax is an estimated $12 to $60 a month at 300 to 600 mcg a day of 0.1% spray, both priced 2026-09-07 through research-chemical channels.The headline numbers overlap at the top of each range, so price is close to neutral. What separates them is verification: dihexa's figure sits before the per-lot HPLC and mass-spec testing its report calls mandatory, which can cost more than the peptide.
Editorial Verdict
Semax scores 7.1 in the strong recommend tier and dihexa 4.4 in the caution tier, and every scored use case in this comparison points the same way. Take semax if you want a nootropic peptide with a human record, understanding that record is Russian post-stroke work rather than healthy-adult cognition.Dihexa is a research decision, not a supplement decision. Zero human trials, no validated human dose, and a mechanism that stimulates a pathway oncologists spend careers blocking. For most readers the answer is semax or nothing.
Evidence Quality
Confidence on this pair is low, and it is low for asymmetric reasons. Semax has decades of supervised Russian clinical use but no eligible recent Western RCT or meta-analysis, so its best human anchors are Gusev 2018 in 110 stroke patients and older attention work.Dihexa has no human evidence at all. It also has a negative animal result: Wells 2024 found that PNB-0408 did not protect against motor, weight or cognitive deficits in 40 rats. Weak evidence on one side, absent evidence on the other.

Frequently Asked Questions

Is dihexa or semax better?: Semax, clearly. It scores 7.1 against dihexa's 4.4 and wins every scored cognitive use case: cognition focus 6.5 to 5.0, memory 6.0 to 5.5, neuroplasticity 6.0 to 5.0, neuroprotection 6.5 to 4.5. Semax also has human data behind it. Dihexa has none. The single exception is a documented research experiment around a neurodegenerative hypothesis.
Why is dihexa scored so low if it's more potent than BDNF?: Because potency measured in rats is not a benefit in a person. Dihexa's rodent synaptogenesis is real and unusually strong, but there are zero human RCTs, zero Phase 1 safety studies and no validated human route or dose. Wells 2024 also found no protection against motor, weight or cognitive deficits in 40 rats, so even the animal record is mixed.
What is the actual cancer concern with dihexa?: Dihexa works by potentiating HGF signaling at c-Met. Comoglio 2008 describes MET as a validated cancer invasion and metastasis target, and capmatinib and tepotinib were approved to block that receptor in MET-altered lung cancer.Dihexa has no carcinogenicity study and no long-term human exposure record. The concern stays theoretical for any individual, but it is pathway biology rather than a vague class worry, which is why cancer history is a hard contraindication.
How fast do they work?: Semax is fast. First noticeable effect in about an hour, assessment window of 2 weeks, full effect at 2 weeks. Dihexa's figures are estimated rather than measured: roughly 2 days to a first change, a 4-week assessment window and full effect at 4 weeks. Semax fails fast, which is a real advantage when neither compound is proven.
Can I stack dihexa and semax?: Don't. The two are mechanistically redundant: both are aiming at neurotrophic plasticity, dihexa through HGF and c-Met, semax through BDNF, TrkB and NGF. Running them together adds cost, sourcing risk and a c-Met exposure you cannot justify, and if you get a benefit or a bad reaction you will not know which compound produced it.
Who should avoid both?: Anyone pregnant or breastfeeding, and anyone competing in drug-tested sport. Dihexa additionally rules out active malignancy, personal or family cancer history, MET-driven tumors and anyone under 18.Semax additionally rules out seizure history, high baseline anxiety, unstable psychiatric symptoms, MAOI therapy and psychiatric medication without clinician clearance. Neither should be used indefinitely with no defined endpoint.
Is semax legal?: It's approved in Russia and sits on its Essential Drugs List, but it is unapproved in the US and sold as a research nasal spray with no product standard. Purity, concentration and storage are vendor-dependent, so purity verification matters. Dihexa has no approved product anywhere and is sold only as a gray-market research chemical.
Has Nick used either of these?: Semax yes, dihexa no. Semax was the first nootropic peptide I tried, and I still use it several times a month, primarily as a nasal spray. The effect feels subtle and situational for me. I have never run a dihexa cycle, and the missing human safety data is exactly why.

Evidence Sources

Preclinical Evaluation of metabolically stabilized angiotensin IV analogs as procognitive / antidementia agents (2013) Rat and cell evidence for dihexa-related synaptogenic and procognitive activity. The anchor citation for dihexa's cognition claim, and it is not human.
Preclinical Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs (2011) Rodent hippocampal synaptogenesis and spatial-memory gains at sub-nanomolar potency, far below typical neurotrophic thresholds.
Preclinical AngIV-Analog Dihexa rescues cognitive impairment and recovers memory in the APP / PS1 mouse via PI3K / AKT signaling (2021) Independent mouse Alzheimer's-model memory rescue signal. The strongest disease-model result dihexa has, still mouse-only.
Preclinical Stem cell, G-CSF and/or dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model (2021) Rat peripheral nerve repair with dihexa combined with mesenchymal stem cells and G-CSF, so dihexa's own contribution is not isolated.
Preclinical Effects of an angiotensin IV analog on 3-nitropropionic-acid-induced Huntington's disease-like symptoms in rats (2024) Negative result: PNB-0408 (dihexa) did not protect against motor, weight or cognitive deficits in 40 rats.
Systematic review Drug development of MET inhibitors in oncology (2008) Frames MET and HGF as a cancer invasion and metastasis pathway and an established oncology drug target. This is the pathway dihexa stimulates.
Label FDA approval summary: capmatinib and tepotinib for metastatic NSCLC harboring MET exon 14 skipping mutations (2022) Confirms approved MET inhibitor drugs for MET-altered lung cancer, which is the safety context for chronic c-Met agonism.
Guideline FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (2026) FDA states it has not identified human exposure data for dihexa acetate and lacks important safety information. Also relevant to semax's US compounding status.
Guideline WADA 2026 Prohibited List (2026) In force from 2026-01-01. Growth factors and growth-factor modulators cover HGF-related compounds; the S0 category catches non-approved substances such as semax.
Observational Semax in combination with rehabilitation in post-ischemic stroke patients (2018) 110 post-ischemic-stroke patients. Semax plus rehabilitation raised plasma BDNF and improved Barthel and motor-recovery scores. Semax's strongest human anchor.
Observational Semax in acute ischemic stroke (1997) 30 semax patients against 80 controls in acute ischemic stroke. Older Russian clinical report pointing the same direction as the 2018 work.
Preclinical Semax affects BDNF and trkB expression in rat hippocampus (2006) BDNF and TrkB upregulation in rat hippocampus after intranasal semax, with a conditioned-learning signal. The mechanistic basis for the neuroplasticity score.
Observational Nootropic analog of adrenocorticotropin 4-10 Semax (1997) Human attention and operative-memory direction. Numbers were not independently verified during the report audit.
Preclinical Protection of episodic memory by Semax in hypoxic-exposed Sprague Dawley rats (2020) Animal hypoxia and novel-object-recognition memory protection. Supports the stress-resilience read without reaching human endpoints.

Glossary

Quick reference for the medical and technical terms used in this comparison.

HGF Hepatocyte Growth Factor: A growth factor that signals through the c-Met receptor and affects cell survival, migration, repair and tumor biology. Dihexa potentiates this signaling.
c-Met MET Receptor Tyrosine Kinase: The receptor HGF activates. MET dysregulation is targeted by oncology drugs such as capmatinib and tepotinib, which is the core safety concern with dihexa.
AT4 Angiotensin IV Receptor: The binding site originally associated with angiotensin IV. Albiston 2001 identified this site as IRAP. Dihexa is an angiotensin IV analog.
IRAP Insulin-Regulated Aminopeptidase: A membrane enzyme that also functions as the AT4 binding site. Its insulin-responsive biology has not produced any dihexa metabolic data.
BDNF Brain-Derived Neurotrophic Factor: A protein supporting neuron survival, synaptic plasticity, learning and memory. Semax's central mechanism, and the marker Gusev 2018 measured in stroke patients.
TrkB Tropomyosin Receptor Kinase B: The main receptor for BDNF. Dolotov 2006 found both BDNF and TrkB upregulation in rat hippocampus after intranasal semax.
ACTH Adrenocorticotropic Hormone: Semax is built from the ACTH 4-7 fragment plus a PGP tail, not from full ACTH, so it lacks the parent hormone's endocrine action.
PGP Pro-Gly-Pro: The tripeptide extension added to ACTH 4-7 to create semax and improve peptide stability.
Synaptogenesis Formation of New Synapses: The growth of new connections between neurons. Dihexa's claimed central mechanism, measured in rodents through dendritic spine density.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I've used semax for years, several times a month, primarily as a nasal spray

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz